Vikas Datt
Managing Partner @ CerraCap Ventures
Vikas Datt is a Managing Partner of CerraCap Ventures.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Vikas Datt invests in
Stages Vikas Datt invests in
Countries Vikas Datt invests in
Investment Focus
Industry
- Biotechnology 2 (40%)
- Medical 1 (20%)
- Security 1 (20%)
- Software 1 (20%)
- Life Science 1 (20%)
Stage
- Venture - Series Unknown 3 (60%)
- Seed 2 (40%)
Country
- United States 3 (60%)
- Israel 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MazeBolt
|
MazeBolt ensures business continuity for global enterprises by validating their DDoS defenses – without the need for maintenance windows. RADAR’s core patented technology continuously runs thousands of nondisruptive simulations, allowing organizations to identify and remediate critical vulnerabilities in their DDoS defenses and configurations, Thisresults in measurable reduction in DDoS risk and stronger regulatory compliance – while preventing the operational, reputational, and financial damages caused by DDoS attacks. | Venture - Series Unknown / Jul 07, 2026 | |
Nephronomics
|
Nephronomics is a precision-medicine biotech company focused on cardio-kidney-metabolic (CKM) and primary renal diseases, using large-scale clinical and genomic data combined with AI to discover and develop targeted therapies. | Seed / Apr 21, 2026 | |
OpsMx
|
OpsMx is Continuous Delivery and Continuous Verification Company with a vision of “ Delivering software without any human intervention”. | Venture - Series Unknown / May 28, 2024 | |
Proxtera
|
Proxtera is a trading network platform designed to facilitate cross-border trade and uplift small and medium enterprises. It uses artificial intelligence to discover prices and sales opportunities, access supply chains, and utilize digital and financial technologies. | Seed / Mar 16, 2023 | |
Totient
|
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble themost potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts. | Venture - Series Unknown / Jan 05, 2021 |
Co-Investors
About CerraCap Ventures
They invest in disruptive companies with potential to dominate global markets. They look for companies and entrepreneurs with fundamentally strong business model. They take the time and effort to understand each idea and decide on its merits and potential through Their comprehensive evaluation process.
CerraCap Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Nikki Arora
Partner/ General Partner
|
|||
Jon Soberg
Venture Partner
|
|||
Ritesh Agarwal
Managing Director
|
|||
Saurabh Ranjan
Founder & Managing Partner
|
|||
|
Vikas Datt
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Vikas Datt invest in?
Vikas Datt invests primarily in Biotechnology, Medical and Security startups, most often at Venture - Series Unknown and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Vikas Datt last invest?
The most recent investment recorded for Vikas Datt closed in Jul 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
